<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708184</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-104</org_study_id>
    <secondary_id>2020-003997-34</secondary_id>
    <nct_id>NCT04708184</nct_id>
  </id_info>
  <brief_title>A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970</brief_title>
  <official_title>A Randomized, Open-label, 3-period, Single-dose, Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of GLPG3970 Given as an Oral Tablet Formulation Versus the Oral Solution Formulation of GLPG3970 and to Assess the Effect of Food on the Oral Tablet Formulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the relative bioavailability of a GLPG3970 oral tablet formulation&#xD;
      compared to an oral solution formulation and the effect of food on the bioavailability of a&#xD;
      single dose of the oral tablet formulation of GLPG3970. It will also evaluate the safety and&#xD;
      tolerability of a single dose of GLPG3970.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Actual">February 25, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3970</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To assess the bioavailability (BA) of a GLPG3970 oral tablet formulation (test) relative to that of an oral solution formulation (reference). To assess the effect of food on BA of a single oral dose of the oral tablet formulation of GLPG3970.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To assess the BA of a GLPG3970 oral tablet formulation (test) relative to that of an oral solution formulation (reference). To assess the effect of food on BA of a single oral dose of the oral tablet formulation of GLPG3970.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero until the last observed quantifiable concentration (AUC0-t)</measure>
    <time_frame>Between Day 1 pre-dose and Day 4</time_frame>
    <description>To assess the BA of a GLPG3970 oral tablet formulation (test) relative to that of an oral solution formulation (reference). To assess the effect of food on BA of a single oral dose of the oral tablet formulation of GLPG3970.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity</measure>
    <time_frame>From Day 1 through study completion, an average of 1 month</time_frame>
    <description>To evaluate the safety and tolerability of a single dose of GLPG3970.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG3970 solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of GLPG3970 in fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 tablet fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of GLPG3970 in fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3970 tablet fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of GLPG3970 in fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 oral solution</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970 solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 tablet</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970 tablet fasted</arm_group_label>
    <arm_group_label>GLPG3970 tablet fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject between 18 and 55 years of age (extremes included), on the date&#xD;
             of signing the informed consent form .&#xD;
&#xD;
          -  A body mass index between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Judged to be in good health by the investigator based upon the results of a medical&#xD;
             history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and&#xD;
             fasting clinical laboratory safety tests, available at screening and prior to&#xD;
             randomization. Total bilirubin, aspartate aminotransferase, and alanine&#xD;
             aminotransferase must be no greater than 1.5x upper limit of normal range. Other&#xD;
             clinical laboratory safety test results must be within the reference ranges or test&#xD;
             results that are outside the reference ranges need to be considered not clinically&#xD;
             significant in the opinion of the investigator.&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to investigational product (IP) ingredients or history of a&#xD;
             significant allergic reaction to IP ingredients as determined by the investigator.&#xD;
&#xD;
        This list only contains the key exclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Tankisheva, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotral Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

